<DOC>
	<DOCNO>NCT01543035</DOCNO>
	<brief_summary>Dyslipidaemia , characterize raise triglyceride low-density lipoprotein ( LDL ) cholesterol reduce high-density lipoprotein ( HDL ) cholesterol level , common HIV-infected individual , associate HIV infection antiretroviral therapy ( ART ) . These abnormality well-established marker cardiovascular ( CVD ) risk general population . Studies suggest increase risk CVD associate ART exposure convey traditional cardiovascular risk factor . In HIV population reduce lipid parameter , usual clinical strategy remain add statin treatment . Recent study suggest ART switch represent interest alternative statin reduce lipid plasma level . The purpose study evaluate frequency replacement LPV/r ( lopinavir/ritonavir ) , ATZ/r ( atazanavir/ritonavir ) , DRV/r ( darunavir/ritonavir ) EFV ( efavirenz ) ETR ( Etravirin ) dyslipidemic patient suppressed viremia would obviate necessity administer statin . A prospective , phase III study statin treatment dyslipidemic HIV patient antiretroviral drug ( ARVs ) interrupt 4 week propose . At week 4 , patient qualify lipid lower drug ( calculate LDL-C≥ 3mmol/L ) replace EFV , LPV/r , DRV/r ATZ/r ETR . The proportion patient qualify anymore statin treatment 12 week ( i.e . 8 week ETR treatment ) determine . Additionally , lipid level change assess 12 week . Inflammatory marker measure baseline , drug switch end study Study drug provide drug manufacturer ( Janssen-Cilag , AG ) . Compliance study drug do week-4 week-12 , Returned study medication count amount notified Case Report Form ( CRF ) .</brief_summary>
	<brief_title>Prospective Evaluation Etravirine HIV-infected Patients Need Lipid-lowering Drugs</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>On statin treatment least 3 month ( fluvastatin , simvastatin , pravastatin , rosuvastatin , atorvastatin ) primary prevention cardiovascular disease HIV Ribonucleic Acid ( RNA ) 50 copies/mL , minimum duration 3 month On stable ( &gt; 3 month ) ARV treatment include least one follow drug : LPV/r , ATZ/r , DRV/r , EFV No previous virological escape virological escape document genotype time failure show K103M mutation . Probability cardiovascular complication &gt; 20 % accord Swiss GSLA ( `` Groupe de travail Lipide et Athérosclérose '' /Swiss Atherosclerosis Association ) guideline Previous cardiovascular disease ( include stroke ) Known diabetes Known intolerance ETR Presence document drug mutation ( exclude K103M ) Regimen include nonboosted ATZ Known hyperlipidemia ARV initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>lipid lower drug</keyword>
	<keyword>etravirine</keyword>
	<keyword>patient</keyword>
	<keyword>statin treatment</keyword>
	<keyword>EFV boost PI antiretroviral treatment</keyword>
</DOC>